Annelation of substituted 3-Hydrazinylimidazo [2,1-c] [1,2,4]triazolone to a series of fused [1,2,4]triazepine and [1,2,4]triazine analogues and evaluation of their anticancer activity
作者:Aisha Y. Hassan、Moshira A. El Deeb、Marwa T. Sarg、Shaimaa I. El Rabeeb
DOI:10.1016/j.tet.2020.131218
日期:2020.6
triazepines 3–7; imidazo[2′,1’:3,4] [1,2,4]triazolo [5,1-c] [1,2,4,6]tetrazepine 8; imidazo[2′,1’:3,4] [1,2,4]triazolo [5,1-c] [1,2,4]triazines 9–15 and imidazo [1,2-d] [1,2,4]triazolo [4,3-b] [1,2,4]triazole analogue 16. Thirteen compounds have been subjected to screening for in vitro anticancer activity. This screening had been conducted at the National Cancer Institute (NCI), USA at a single dose (10-5 M)
进行了一系列新型的咪唑并[2,1-c] [1,2,4]三唑衍生物的新型合成途径。我们新合成的化合物是由反应性双亲核试剂3-肼基-5-(4-甲氧基亚苄基)-7-苯基-5 H-咪唑[2,1-c] [1,2,4]三唑-6(7 H)-2采用不同的综合策略。退火后的衍生物是不同的咪唑并[2',1':3,4] [1,2,4]三唑并[5,1-c] [1,2,4]三氮杂卓3-7 ; 咪唑并[2',1' :3,4] [1,2,4]三唑并[5,1-C] [1,2,4,6] tetrazepine 8 ; 咪唑[2',1':3,4] [1,2,4]三唑[5,1-c] [1,2,4]三嗪9-15和咪唑[1,2-d] [1, 2,4]三唑[4,3-b] [1,2,4]三唑类似物16。已经对十三种化合物进行了体外抗癌活性的筛选。(10该筛选已在单次剂量在美国国家癌症研究所(NCI),美国进行的- 5 M)对全NCI